Pituitary Diseases

Adenovirus Delivery Of Gene Therapy Appears Safe

Published in Vaccine Weekly, March 14th, 2001

by N.R. Saltmarsh, staff medical writer -- Scientists have identified adenovirus vectors as useful carriers for gene therapy of pituitary diseases, but were uncertain how long the treatment method would be effective.

In a recent study, T.D. Southgate and colleagues measured tissue levels of therapeutic genetic material over three months to determine both the longevity of the treatment effect and its potential safety. They found that genetic material could be observed in the pituitary three months later, though in decreasing amounts, and that pituitary hormones were not adversely affected.

After using an adenovirus vector to deliver herpes simplex...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-03-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry